P641: REAL-WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA

• DOI: 10.1097/01.hs9.0000969468.03128.c0
• Publication Date: 2023-08-22T02:07:28Z
• Authors: Anna Teschemaker; Shweta Hakre; Jenny Tse; Nazneen Fatima Sh...; Yifan Gu; Aimee Near
• Keywords: Obinutuzumab; Discontinuation; Regimen; Venetoclax; Bendamustine; Chlorambucil; International Prognostic Index

Background: Venetoclax (V) is an approved fixed-duration treatment for chronic lymphocytic leukemia and small lymphoma (CLL/SLL), either as a 12-cycle regimen (~12 months) in combination with obinutuzumab (O) the first-line (1L) setting or 24-cycle (~24 rituximab (R) relapsed/refractory (R/R) setting. Aims: To analyze real-world patterns of V+O 1L V+R R/R settings patients CLL/SLL United States. Methods: A retrospective cohort analysis was conducted using IQVIA PharMetrics® Plus database to identify aged ≥18 years treated (1L cohort; May 2019 September 2021) (R/R June 2018 2021). The start defined index date. All were required have ≥1 diagnosis code CLL/SLL, 12 months continuous enrollment (CE) prior date, ≥3 CE after Duration (DoT) time from date earliest discontinuation (defined ≥60-day gap V prescription refills) censoring end follow-up). Fixed-duration cycle 12- dosing, corresponding days 336−364 707−735 setting, based on dosing schedule plus 28 days. Kaplan-Meier used estimate probability remaining cohorts. Results: total 116 (mean age, 62.3 years; 73.3% male) 145 64.2 73.8% identified; 48.3% had targeted therapy. median (95% CI) DoT (n=115) 12.4 (11.5, 13.4) over follow-up 11.4 months; at 12, 18, 24 56.4%, 20.2%, 5.1%, respectively. (n=133) 24.5 (13.4−25.2) 15.5 24, 30, 36 53.8%, 19.0%, Among V+O, 47.8% (55/115) ≥12 follow-up, whom 9.1% fixed cycles 38.2% discontinued early (median DoT: 4.6 months). V+R, 29.3% (39/133) ≥24 5.1% 46.2% 7.1 each >12 (Table). Summary/Conclusion: While approximately settings, respectively, high number did not maintain fixed-dosing schedule. This study provides evidence that V-based approach may be suitable all CLL/SLL. Future studies should include additional larger sample, reasons discontinuation, patient molecular genetic profile.Keywords: Venetoclax, Chronic leukemia, Real world data